Cetuximab (Erbitux)

Cetuximab at a glance

The verified brand is Erbitux. Cetuximab is a monoclonal antibody, a laboratory-made protein designed to attach to a particular target. Its main target is the epidermal growth factor receptor, or EGFR, on cells. It is classified as targeted therapy.

Treatment is given under specialist supervision, usually once a week or once every two weeks, according to the complete plan. Some schedules include other cancer medicines or radiotherapy. A tablet prescribed alongside cetuximab is a separate medicine with its own instructions.

Skin and nail changes are particularly important. Magnesium and other blood salts can fall even when you feel well, so blood tests continue during treatment and may be needed afterwards. Serious infusion reactions can occur despite preventive medicines, especially during the first appointment.

The aim is to recognise problems early enough for the team to treat them and adjust treatment when necessary. Reporting a rash or a symptom does not automatically mean treatment has failed or must permanently stop.

What cetuximab is and how it works

EGFR receives signals that help cells grow and divide. Cetuximab attaches to the outside of this receptor and interferes with those signals. It can also help immune cells recognise and attack cells carrying the target. These antibody-related immune effects do not make it the same treatment as a checkpoint inhibitor such as pembrolizumab.

Some cancer-cell changes can keep growth signals active further along the pathway even when EGFR is blocked. This is why the right tumour tests matter. The presence of a target alone does not guarantee benefit, and a result used for one treatment plan may not be relevant to another.

EGFR also has functions in healthy skin and other tissues. Blocking it helps explain the characteristic rash and related problems. “Targeted” does not mean side effects will always be mild or limited to the cancer. The team balances the expected benefit against your health and treatment risks.

How the team decides whether it is suitable

The oncologist considers the precise diagnosis, tumour test results, earlier treatment, general health and accompanying medicines. Ask which results support your plan and what will be used to assess response.

When cetuximab is considered for colorectal cancer, the tumour's RAS status is important. Testing includes KRAS and NRAS. “Wild type” means the tested gene changes were not found; it does not mean that every gene in the tumour is normal. Cetuximab should not be used in the relevant colorectal treatment setting when RAS is mutated or its status is unknown.

A BRAF V600E result is relevant when an encorafenib-containing plan is proposed. BRAF and RAS are different tests, and the specialist must interpret the whole result and regimen. Tumour testing does not by itself show that a change was inherited.

Tell the team about heart disease, abnormal heart rhythms, breathing problems, severe dry eyes or previous inflammation of the eye surface. Mention contact-lens use, liver or kidney disease, and previous reactions to cetuximab or other infusions. Severe organ impairment needs particular assessment because experience is limited.

Before treatment starts

Baseline blood tests generally check blood counts, kidney and liver function, and salts including magnesium, potassium and calcium. An ECG or additional heart assessment may be arranged when your history or treatment combination warrants it. Pregnancy status should be checked when relevant.

The team reviews your skin, mouth, nutrition and medicines. Ask whether you should start a preventive skin-care plan before the first infusion. European prescribing information advises considering an oral tetracycline antibiotic course and topical treatment to reduce skin problems. These medicines must be prescribed for you; do not start leftover antibiotics or steroid cream yourself.

Red-meat allergy and tick bites

Tell the team about an allergy to red meat, previous tick bites or a known alpha-gal allergy. Alpha-gal is a sugar molecule that can be involved in a particular allergic response. Antibodies against it can increase the risk of a serious reaction to cetuximab. This can happen on the first exposure to the medicine.

The current US information advises considering an alpha-gal antibody test before treatment. A negative result does not eliminate the risk, and not every tick bite means treatment is impossible. Your specialist must assess the history and alternatives and arrange appropriate supervision. Preventive medicines and observation are still needed.

Prepare for the first visit

Allow time for blood results, review, preventive medicines, the infusion and observation afterwards. Arrange transport if the antihistamine makes you sleepy. Bring your full medicine list and the hospital's contact details, and ask how to obtain urgent advice after leaving the unit.

How cetuximab is given

The infusion and treatment schedule

A nurse gives cetuximab through a small cannula in an arm or hand, or through a central venous line or implanted port. It is an intravenous infusion, not a tablet, a routine injection under the skin or a medicine to give yourself at home. Tell the nurse immediately about pain, burning, redness, swelling or leakage around the line.

Dosing is often based on body surface area, calculated from height and weight. A weekly schedule commonly starts with 400 mg/m² over about two hours, followed by 250 mg/m² over about one hour at later visits if tolerated. An every-two-week schedule uses 500 mg/m² over about two hours. These are labelled examples, not instructions to select or calculate your own dose.

The appropriate schedule depends on the accompanying treatment. Weekly and fortnightly appointments are not interchangeable simply for convenience. With chemotherapy, the prescribed sequence generally leaves at least an hour after cetuximab before chemotherapy starts. Radiotherapy and encorafenib also have specific coordination instructions. Follow the unit's full calendar.

Medicines before the infusion

You receive preventive medicine to reduce infusion reactions. The US label specifies an intravenous H1 antihistamine 30–60 minutes before the first dose, with later use as clinically necessary. European information specifies an antihistamine and corticosteroid at least an hour before the first dose and recommends them before subsequent doses. The team follows the applicable product and local protocol.

Premedication lowers risk but does not prevent every reaction. Do not stay quiet about new symptoms because you have already had an antihistamine. The nurse can stop or slow the infusion and provide treatment. A serious infusion reaction requires permanent discontinuation.

Observation and later appointments

You are monitored during each infusion and for at least an hour afterwards. A reaction may require longer observation. The first visit is often longer, and future infusion speed may remain slower if you previously reacted. Symptoms can also start several hours later, so keep the urgent-contact plan available at home.

If you miss an appointment, call the unit to arrange the next step. Do not try to make up treatment elsewhere without coordination. Vomiting after an infusion does not remove the medicine already given into the bloodstream and is not a reason for a replacement dose. Repeated vomiting still needs assessment.

Formulation and storage

Erbitux solutions have different concentrations in the reviewed US and European products: 2 mg/mL and 5 mg/mL respectively. The pharmacy calculates the correct volume. Patients and caregivers should not transfer a preparation instruction between products or arrange a substitution themselves.

The hospital normally stores and prepares the medicine. Unopened vials require refrigeration at 2–8°C (35.6–46.4°F) and must not be frozen. The US information also says not to shake them. If you are asked to collect or transport a supply, obtain the pharmacy's written storage and transport plan; do not use an ordinary bag for prolonged hot-weather transport.

Monitoring and checking whether treatment is working

Blood salts need attention throughout treatment. The US label specifies weekly magnesium, potassium and calcium checks during treatment and continued monitoring for at least eight weeks after it ends. European information specifies testing before and periodically during treatment. Your team should give you the actual schedule, including tests after the last infusion.

Low levels may require replacement by mouth or through a drip. Do not start supplements or change their dose independently: the choice depends on blood results, symptoms, kidney function and other treatment. Diarrhoea can worsen salt and fluid losses.

Reviews also assess the skin, nails, mouth, eyes, breathing, weight and ability to eat or drink. Blood counts and liver and kidney tests are particularly important when other medicines are included. Tell the team if a symptom is affecting sleep, walking, personal care or eating, even if it seems too minor for an emergency call.

Scans and other disease assessments check whether treatment is helping. A rash alone cannot establish benefit for an individual patient, and the absence of a rash does not prove failure. Ask when response will be assessed and which findings would lead to a change in treatment.

Common side effects and practical care

Acne-like rash and dry skin

A spotty rash often affects the face, scalp, upper chest or back and commonly starts early in treatment. It may itch, feel tender or be accompanied by dryness and cracks. This is a treatment-related skin reaction, not necessarily ordinary acne. Report it promptly rather than waiting until it becomes painful or infected.

Wash gently with lukewarm water and a mild, unperfumed cleanser. Use the moisturiser recommended by the team. Avoid harsh scrubs, alcohol-containing products and over-the-counter acne preparations unless specifically advised. Prescribed creams, antibiotics or a treatment pause may be needed.

Protect your skin from sunlight with clothing, shade and sunscreen of at least SPF 30. US advice continues limiting sun exposure for two months after the last dose. Skin recovery may take time, so stopping the infusion course does not mean all skin precautions can stop immediately.

Nails and hair

The skin around nails can become sore, swollen or infected. Nails may become brittle or loose. Keep them clean, protect hands from repeated wet work or chemicals and report painful redness, discharge or difficulty using your hands. Avoid picking at the cuticles or attempting to drain an infection.

Hair can become thinner or change texture. Facial hair and eyelashes may grow more, rather than less. If long eyelashes rub the eye, ask for professional help; do not trim them near the eye yourself. Other medicines in the regimen may cause a different degree of hair loss.

Mouth soreness and appetite

Mouth soreness can make eating and drinking difficult, particularly with accompanying treatment. Use gentle mouth care and a soft toothbrush. Ask about prescribed rinses and pain relief. Softer foods may be easier, while acidic, spicy or very hot foods may sting. Report ulcers, swallowing pain or a persistent reduction in intake.

A dietitian can help if weight is falling or the treatment affects chewing and swallowing. Do not accept poor intake as inevitable: early support may prevent dehydration and interruptions to treatment.

Diarrhoea, nausea and tiredness

Use the anti-sickness or anti-diarrhoea plan supplied by your team. Report a clear increase from your usual bowel pattern, especially with pain, fever, blood, dizziness or reduced urine. If you have a stoma, a marked increase in output also matters. Do not wait several days when symptoms are worsening.

Drink within the limits agreed for your heart and kidney health. Smaller meals may help nausea. Balance rest with gentle activity you can manage, but report severe or unexpected fatigue because low blood salts, dehydration, anaemia or infection may contribute.

Important side effects needing prompt assessment

Infusion reactions and severe allergy

Symptoms can include flushing, itching, hives, chills, fever, wheezing, hoarseness, throat tightness, dizziness or chest discomfort. Tell the nurse immediately during treatment. After discharge, severe breathing difficulty, swelling of the face or throat, collapse or chest pain requires emergency care. Reactions may occur despite premedication or a negative alpha-gal test.

Low blood salts and heart problems

Low magnesium, potassium or calcium can cause cramps, tremor, tingling, marked weakness or palpitations. Contact the hospital promptly. A seizure, fainting with ongoing symptoms, chest pain or collapse needs emergency assessment. Blood tests can detect changes before symptoms develop.

Serious heart and breathing events have occurred with cetuximab, particularly in certain combinations. Tell the team about existing heart disease and any new chest pain, breathlessness or abnormal heartbeat. Do not assume such symptoms are only anxiety or fatigue. Monitoring continues after treatment because some risks do not end with the last infusion.

Lung inflammation and blood clots

New or worsening cough, breathlessness or fever needs prompt investigation. Cetuximab can cause inflammation within the lungs, called interstitial lung disease. Infection, a clot and other causes may produce similar symptoms. The team must interrupt or stop treatment for new or worsening lung symptoms while investigating. Confirmed interstitial lung disease requires permanent discontinuation. Severe breathlessness is an emergency.

A new painful swollen arm or leg requires urgent assessment for a clot. Sudden chest pain, coughing blood, severe breathlessness or collapse requires emergency care. Cancer and the whole treatment plan influence clot risk, so a symptom should not be dismissed because it is not a common cetuximab effect.

Serious skin infection or blistering

Rapidly spreading redness, severe skin pain, fever, pus or feeling acutely unwell may indicate infection. Rarely, skin infection can become deep or enter the bloodstream. Widespread blistering or peeling, especially with sores in the mouth or eyes, needs emergency assessment. Do not treat these changes as routine acne.

Eye problems

Contact the team urgently about a painful or red eye, new light sensitivity, blurred vision or worsening dryness. Inflammation or ulceration of the cornea, the clear front surface of the eye, may damage vision. Specialist eye assessment and a treatment pause may be needed. Mention contact lenses and do not simply continue wearing them over a painful eye.

Other medicines, supplements and vaccinations

Give the team an up-to-date list of prescriptions, over-the-counter medicines, vitamins and herbal products. Cetuximab does not have the same set of food and liver-enzyme interactions as an oral kinase inhibitor, but the full treatment plan can introduce important interactions. Do not assume a supplement is safe because it is natural.

Chemotherapy, radiotherapy and encorafenib can add different skin, bowel, blood-count, heart or other risks. Your team selects the combination and monitoring together. A pause in cetuximab does not automatically mean you should stop or continue every other medicine unchanged; confirm each instruction.

Ask about vaccinations before booking them. Non-live vaccines may be recommended, while suitability and timing of live vaccines depend on immune function and accompanying treatment. There is no single waiting period that applies to every cetuximab plan. Tell other clinicians and dentists about your treatment before procedures.

Everyday life during treatment

Cetuximab itself does not require fasting because it is given into a vein. Eat and drink as advised for your appointment; separate medicines or tests may have their own rules. Keep skin-care products, a symptom record and prescribed supportive medicines available at home.

Skin changes can affect comfort, appearance, confidence and intimacy. Ask for help with symptoms and emotional effects rather than feeling that you must tolerate them silently. Comfortable clothing and avoiding repeated friction may help irritated areas.

Do not drive or use machinery if you are sleepy after premedication, dizzy, weak or unable to concentrate. Discuss work and travel around infusion visits and blood tests. If travelling, know where to seek urgent care and protect the medicine schedule from missed appointments. No level of sun protection makes prolonged intense exposure advisable.

Fertility, contraception, pregnancy and breastfeeding

Cetuximab can harm a developing baby. Pregnancy testing is needed before treatment when applicable. US guidance advises effective contraception during treatment and for two months after the last dose for patients who could become pregnant. European information requires attention to adequate contraception but does not give the same numerical post-treatment contraception interval. Obtain a written plan for the supplied product and complete regimen.

The reviewed cetuximab labels do not specify a separate fixed male contraception interval. Partner medicines may impose additional requirements. If encorafenib is included, its US instructions require a nonhormonal method because hormonal contraception may be less effective; its shorter two-week interval must not shorten cetuximab's applicable precautions. Other partners can require longer periods.

Do not breastfeed during cetuximab treatment or for two months after the last infusion. Follow any longer restriction required by another medicine. Tell the team promptly if pregnancy is suspected in you or a partner.

The effect on human fertility is uncertain; animal findings suggest a possible effect on female fertility. Discuss sperm or egg preservation before starting if future parenthood matters to you. Absent periods or reduced fertility do not replace contraception.

After treatment finishes or changes

Keep all planned blood tests after the last infusion. In particular, the US label continues electrolyte monitoring for at least eight weeks. Replacement treatment may still be needed. Continue skin care and sun precautions; US advice limits sun exposure for two months after the last dose.

Report persistent rash, nail infection, eye symptoms, breathing changes or severe weakness rather than assuming they cannot be treatment-related. Retain the reproductive and breastfeeding precautions for the full required period.

Ask for a written summary of your last dose, any significant reaction, monitoring still needed and the next response assessment. If treatment was paused, the specialist decides whether and how it restarts. A delay for safety is different from a decision that the treatment is no longer useful.

Frequently asked questions